Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Publisher
Cardiovascular Diabetology(1)
Stroke(1)
The Lancet Diabetes and Endocrinology(1)
The Lancet Neurology(1)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopusRivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy
ArticleAbstract: Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not knownPalabras claves:aspirin, COGNITION, infarction, rivaroxaban, white matterAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Dagenais G.R., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Fox K.A.A., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Reeh K.W., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Yusuf S., Zhu J.Fuentes:googlescopusThe effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptPalabras claves:Autores:Atisso C.M., Avezum A.J., Basile J.N., Botros F.T., Colhoun H.M., Conget I., Cushman W.C., DIaz R., Dyal L., Gerstein H.C., Hall S., Hâncu N., Hanefeld M., Hart R.G., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
ArticleAbstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) doublePalabras claves:Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 DiabetesAutores:Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopus